FDA Approves Bunavail for Opioid Addiction

June 26th, 2014

The US Food and Drug Administration (FDA) has approved a new drug for the maintenance treatment of opioid dependence.

BioDelivery Sciences International Inc announced in a release that it has received FDA approval of Bunavail (buprenorphine and naloxone) buccal film (CIII) and expects to launch the drug late in the third quarter of 2014.

According to the manufacturer, the drug has a unique adhesive “inside the cheek” delivery system that improves absorption and plasma concentrations of buprenorphine and therefore can be delivered at a lower dose, which may help reduce the potential for misuse and diversion and lessen the incidence of side effects.

The company asserts that unlike sublingual products that need to be kept in place under the tongue until they dissolve, the inside-the-cheek film allows patients to talk, swallow, and go about normal daily activities while the medication is being consistently absorbed.

To read more, click here.

Posted in SBIRT

A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.